Ace the Case: 79-Year-Old Man With Lower Back Pain, Increasing Fatigue, and Right Rib Pain healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Oncopeptides completes patient enrollment in phase 2 PORT study
News provided by
Share this article
Share this article
STOCKHOLM, May 5, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has completed patient enrollment in the phase 2 PORT study. The PORT study is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous administration of melflufen (INN melphalan flufenamide) in combination with dexamethasone in relapsed refractory multiple myeloma. Oncopeptides expects topline data in Q3 2021. I am very pleased that we have enrolled the final patient in the PORT study, said Klaas Bakker, MD, PhD and Chief Medical Officer at Oncopeptides. The data could potentially provide a pathway for us to work with the U.S. Food and Drug Administration to
Metformin may help prevent some breast cancers, study says
By (0)
Women with type 2 diabetes may be more likely to develop breast cancer, but taking the diabetes drug metformin appears to reduce their risk for the most common type, new research finds.
Compared to women without diabetes, risk for estrogen-positive breast cancer was 38% lower among women with type 2 diabetes who had used metformin for 10 years or more.
Advertisement
Metformin did not protect against estrogen receptor-negative breast cancer and may increase risk for triple-negative breast cancers, the study found. Women with type 2 diabetes and their doctors should consider whether their type 2 diabetes diagnosis and treatment should influence how frequently they are screened for breast cancer, said study author Dale Sandler, chief of the epidemiology branch at the U.S. National Institute of Environmental Health Sciences in Research Triangle Park, N.C.